FDA approved Merck & Co’s Ebola vaccine Ervebo

The U.S. Food and Drug Administration said on Thursday it approved drugmaker Merck & Co’s  Ebola vaccine Ervebo, making it the first FDA-authorised vaccine against the deadly virus.

The vaccine was used by the World Health Organization and Democratic Republic of the Congo as an investigational vaccine to help reduce Ebola virus disease (EVD) outbreaks in few West African countries from 2014 to 2016, reports Reuters.

The Ebola virus, which causes haemorrhagic fever and spreads from person to person through direct contact with body fluids, has killed more than 2,100 people in Congo since the middle of the year, making it the second-largest Ebola outbreak in history.

The vaccine, which is administered as a single-dose injection, will help to prevent EVD caused by Zaire ebolavirus in patients aged 18 years and older, the regulator said in a statement.

Merck welcomed the FDA’s decision, describing it as an important milestone in the fight against the deadly virus.

In November, Merck received approval from the European Commission to market Ervebo, less than a month after a European medicines panel backed the first-ever vaccine against the virus.

News Hour Correspondent

This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts

Bangladeshi community radios broadcasting 25 hours program on COVID-19 prevention education
Global lockdown tightens as coronavirus deaths mount
Tom Hanks, Rita return to US after coronavirus quarantine in Australia
Rotterdam concert hall to admit coronavirus patients instead of Eurovision fans
ADB backs China Gas to assure constant gas supplies to combat COVID-19 in Hubei province

Advertisement

News of the Month

December 2019
S M T W T F S
« Nov   Jan »
1234567
891011121314
15161718192021
22232425262728
293031  
Scroll Up
%d bloggers like this: